Upsher-Smith adds Zembrace SymTouch injection to its Access Pathways Platinum Pass Savings program
Upsher-Smith has added Zembrace SymTouch (sumatriptan) injection 3 mg to its Access Pathways Platinum Pass Program, a savings and support program where eligible patients pay $0 per prescription.
Zembrace SymTouch is indicated for the acute treatment of migraine with or without aura in adults. It provides migraine pain relief in as little as 10 minutes for some patients.
Zembrace SymTouch joins Qudexy XR (topiramate) extended-release capsules and Tosymra (sumatriptan) nasal spray as part of Upsher-Smith’s portfolio of medications supported by the program.
The Access Pathways Program is a best-in-class co-pay program designed to reduce out-of-pocket costs for patients and improve prescribing confidence for healthcare professionals.
“Minutes matter to migraine patients who are seeking fast pain relief,” Upsher-Smith president and CEO Rusty Field said. “By adding fast-acting Zembrace SymTouch to the Access Pathways Program, we are able to assist patients by reducing some of the barriers associated with access and affordability, along with challenges that healthcare professionals face when prescribing.”